A COMPARATIVE CLINICAL STUDY OF DURALABHADI LEHA ANDINDRAVARUNIKADI CHURNA IN THE MANAGEMENT OF TAMAK SHWASA WITHSPECIAL REFERENCE TO PRINCIPLE तमके तॠविरेचनम(च.चि. 17/121)
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Change in the clinical symptoms ofTamak shwasa. 1.Shwasakrichhta (Dyspnoea)
研究概览
简要总结
Need of the study-
Modern science manages Tamak Shwasa (Bronchial Asthma) by administration of bronchodilators and corticosteroids with long acting beta agonist. Which have serious adverse effects like nausea, vomiting, tremors and huskiness of voice and have limitation for a high time therapy due to drug dose dependency. It is required to find out a potential remedy for Tamak Shwasa (Bronchial Asthma) which is easily compatible with the human body. There is a need to find out a treatment which is safer, effective, non-toxic and cheaper. Such remedies could be explored from the huge wealth of Ayurveda.
Aims and objective of the study-
To compare the efficacy of ’Duralabhadi leha’ alone and ’Indravarunikadi churna’ alone in the management of the Tamak shwasa.
Hypothesis-
’Duralabhadi leha ’ is more effective than
’Indravarunikadi churna ’in the management of Tamak shwasa.
Null hypothesis--
There is no difference between the efficacy of ’Indravarunikadi churna’ and ’Duralabhadi leha’ in the management of Tamak shwasa.
Alternate hypothesis-
’ Indravarunikadi churna’ is more effective than ’Duralabhadi leha’ in the management of Tamak shwasa.
Lab investigations- 1. ESR, CBC.
- Spirometry.
研究设计
- 研究类型
- Interventional
- 分配方式
- Computer generated randomization
- 盲法
- Open Label
入排标准
- 年龄范围
- 18.00 Year(s) 至 60.00 Year(s)（—）
- 性别
- All
入选标准
- •Ages ranging from 18 years to 60 years.
- •Those ready to give written informed consent.
- •Patient present with sign and symptom of Tamak shwasa.
- •Eligible patient able to participate for 8 weeks.
排除标准
- •Patients with severe bronchial asthma.
- •Patients present with associated morbid disorder.(TB etc.) Patient with poorly controlled hypertension (i.e. systolic >160 mm of HG and diastolic >100 mm of HG) Pregnancy or lactating women.
- •Patients with alcohol dependence.
- •H/o Hypersensitivity to the trial drugs or any of its ingredients.
- •Patient with evidence of malignancy.
- •Symptomatic patient with clinical evidence of heart failure.
结局指标
主要结局
Change in the clinical symptoms ofTamak shwasa. 1.Shwasakrichhta (Dyspnoea)
时间窗: 60 days
2.Peenasa ( Nasal discharge)
时间窗: 60 days
3.Kasa (Cough)
时间窗: 60 days
4.Kapha nishatheevana (Expectoration)
时间窗: 60 days
5.Ghurghurakam shabda (Wheezing)
时间窗: 60 days
6.Urahshoola (Chest pain)
时间窗: 60 days
次要结局
- 1. Change in the laboratory parameters.(2. Frequency)